Published in Vasc Health Risk Manag on April 03, 2014
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell (1991) 11.51
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 5.21
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost (2005) 4.64
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
A dual thrombin receptor system for platelet activation. Nature (1998) 3.96
Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A (1998) 3.50
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest (1999) 3.16
A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol (1985) 3.02
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol (2007) 2.73
Defective platelet activation in G alpha(q)-deficient mice. Nature (1997) 2.67
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J (2011) 2.21
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 2.20
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 2.13
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet (2012) 2.00
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol (2013) 1.94
Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke (2013) 1.79
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J (2013) 1.56
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol (2013) 1.51
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2011) 1.33
Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost (2008) 1.26
Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation (2013) 1.13
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol (2011) 1.09
Basic principles of platelet biology and clinical implications. Circ J (2010) 1.09
Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J (2009) 1.07
Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood (2003) 1.05
Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg (1996) 1.04
Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem (1991) 0.99
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost (2005) 0.97
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol (2003) 0.95
Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb (2011) 0.94
Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem (2004) 0.93
PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler Thromb Vasc Biol (2002) 0.93
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs (2012) 0.92
Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost (2012) 0.92
Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost (2002) 0.91
Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost (2004) 0.87
Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res (2008) 0.86
Discovery of a vorapaxar analog with increased aqueous solubility. Bioorg Med Chem Lett (2010) 0.86
Endothelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac Surg (1997) 0.84
Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett (1999) 0.83
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol (2013) 0.81
Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol (2012) 0.81
Stimulus-induced release of endogenous catecholamines from human washed platelets. Clin Sci (Lond) (1986) 0.80
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol (2011) 0.80
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost (2014) 0.80
New directions in antiplatelet therapy. Circ Cardiovasc Interv (2012) 0.80
Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev Cardiovasc Ther (2010) 0.79